![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Eli Lilly’s Second Potential COVID-19 Antibody Enters Phase 1 Trial
Eli Lilly’s Second Potential COVID-19 Antibody Enters Phase 1 Trial
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/China_Map.gif?t=1478215210&width=430)
Eli Lilly and Junshi Biosciences have begun a phase 1 trial of a second neutralizing antibody for COVID-19.
The trial led by Junshi in China will evaluate the safety and tolerability of the antibody, JS016, in healthy participants who have not been diagnosed with COVID-19. Eli Lilly also plans to begin a phase 1 trial of the antibody in the U.S. soon.
The companies last week began a phase 1 trial of a separate COVID-19 antibody, LY-CoV555.
Upcoming Events
-
21Oct